What a New Meta-Analysis Found About Retatrutide, Blood Pressure and Lipids

What Did This New Meta-Analysis Actually Study?

A systematic review and meta-analysis published in High Blood Pressure & Cardiovascular Prevention pooled data from published randomised controlled trials of retatrutide, the investigational GIP/GLP-1/glucagon triple-receptor agonist still completing Eli Lilly's TRIUMPH Phase 3 programme.[1] Rather than reporting a single trial's results, as most retatrutide coverage does, the authors — Luis E. Simental-Mendia, Laura Jazel Barragan-Zuniga and Valeria Reyes-Avitia — statistically combined outcomes across multiple retatrutide RCTs to produce pooled weighted mean differences (WMD) for blood pressure and lipid markers, a standard evidence-synthesis method used to increase statistical power beyond what any one trial can offer.[1]

This is an independent academic publication, not an Eli Lilly-authored release. It sits alongside a small but growing body of third-party meta-analyses that re-examine Lilly's own trial disclosures using formal evidence-synthesis statistics rather than single-study press releases.

What Did the Meta-Analysis Find for Blood Pressure?

Low heterogeneity matters in meta-analysis: a wide spread between trial results (high I²) can mean an average figure is masking real disagreement between studies, while a low I² on both blood pressure endpoints suggests the pooled estimate is a reasonably stable summary of what retatrutide's trial programme has shown so far on this specific marker.

What Did It Find for Cholesterol and Triglycerides?

The same pooled analysis reported significant reductions across three of the four standard lipid markers measured: total cholesterol fell by a weighted mean of 21.88 mg/dL (95% CI −27.79 to −15.97, p<0.0001), LDL-C fell by 13.10 mg/dL (95% CI −16.10 to −10.10, p<0.0001), and triglycerides fell by 40.90 mg/dL (95% CI −48.50 to −33.30, p<0.0001).[1]

Source: Simental-Mendia LE, Barragan-Zuniga LJ, Reyes-Avitia V. Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels. High Blood Press Cardiovasc Prev. 2026.[1]

Unlike the blood pressure figures, the total cholesterol result carries high statistical heterogeneity (I²=84%), meaning the individual trials pooled into that figure disagreed substantially with each other — likely reflecting differences in dose, trial population and follow-up duration across retatrutide's Phase 2 and Phase 3 programme. The triglyceride and LDL-C findings sit at moderate heterogeneity (I²=53% and 47%), which is a more typical range for pooled clinical-trial lipid data.

Why Didn't HDL Cholesterol Move?

This pattern — substantial LDL-C and triglyceride reduction alongside an essentially unchanged HDL-C — has also been observed with other GLP-1-class and multi-agonist incretin therapies, where the dominant driver of lipid change appears to be weight loss and reduced hepatic lipid flux rather than a direct effect on HDL metabolism. It is a mechanistic detail, not a safety signal, but it is exactly the kind of nuance that gets lost when a single topline percentage figure is repeated without the underlying breakdown.

How Does This Compare With Single-Trial TRIUMPH Data?

Velox Peptides has separately covered TRIUMPH-1's own cardiometabolic secondary endpoints, presented at ADA 2026, which reported a 41% fall in triglycerides, a 24.2% fall in non-HDL cholesterol and a 12.3 mmHg fall in systolic blood pressure at 80 weeks in the 12 mg arm specifically.[2] Those numbers are larger than this meta-analysis's pooled averages because TRIUMPH-1 reports its own highest-dose arm at a single, later timepoint, while the meta-analysis averages across multiple trials, doses and follow-up periods, and expresses lipid changes in absolute mg/dL rather than percentage change from baseline.[1]

Neither figure is "wrong" — they answer different questions. A single trial's topline result tells researchers what the highest studied dose achieved in one specific population at one specific week. A pooled meta-analysis tells researchers whether an effect holds up, and how consistently, across the whole published evidence base to date. Reading both together, rather than either in isolation, is closer to how the effect should actually be interpreted.

What Are the Limits of Pooling Trial Data This Way?

Meta-analyses inherit the limitations of the trials they pool. Retatrutide's underlying RCTs vary in dose (2 mg to 12 mg), population (obesity alone, obesity with type 2 diabetes, obesity with established cardiovascular disease) and follow-up length, and none of the source trials were designed with blood pressure or lipid change as their primary endpoint — those are secondary or exploratory measures reported alongside the headline weight-loss result. High heterogeneity on the total cholesterol figure (I²=84%) is a direct signal of that underlying variability, and readers should treat that particular pooled estimate with more caution than the low-heterogeneity blood pressure figures.

It is also worth restating plainly: retatrutide remains an investigational compound with no marketing authorisation from the MHRA, FDA or EMA.[3] A statistically significant pooled trial finding describes what has been measured in Eli Lilly's clinical trial participants under close medical supervision — it is not a therapeutic claim, a dosing guide, or evidence of an effect in any other setting.

What Should UK Researchers Take From This?

This meta-analysis is a useful reference point for researchers tracking retatrutide's published evidence base as an independent, methodologically distinct cross-check on Eli Lilly's own single-trial disclosures. It has no bearing on the regulatory status of research-use peptides in the UK: retatrutide remains unapproved for human use everywhere, and nothing here changes the position set out in our guide on whether research peptides are legal in the UK. For more on the compound's proposed biological pathway, see our guide to retatrutide's mechanism of action.

Velox Peptides supplies retatrutide strictly as an HPLC-verified in vitro research reagent, with batch documentation available on request and no dosing guidance of any kind.

Retatrutide is referenced here for research-news context only. Where supplied by Velox Peptides, it is a research reagent, not a medicine, and has not been evaluated by the MHRA, FDA or EMA in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions